A group of Takeda Pharmaceutical stakeholders, including retired managers, sent an open letter to the drugmaker’s president, demanding more transparency on the megadeal.
The group calls themselves "Thinking about Takeda's Bright Future," is made up of around 130 Takeda alumni and other individual investors.
The letter to Takeda President Christophe Weber probed for a more detailed explanation of Takeda’s plans to pay back the debt that will finance the $62B acquisition. The shareholders also asked Weber to further justify the 65% premium for Shire, make public the board meeting minutes along with statements by execs, and address other acquisition targets.
Read the Nikkei Asian Review coverage